Hostname: page-component-77f85d65b8-45ctf Total loading time: 0 Render date: 2026-03-27T06:42:02.685Z Has data issue: false hasContentIssue false
  • English
  • Français

Novel use of trametinib for treatment of atrial arrhythmia in absence of cardiomyopathy in a patient with Costello syndrome

Published online by Cambridge University Press:  06 January 2025

Andrew S. Kato Open the ORCID record for Andrew S. Kato [Opens in a new window] ,
Natalie S. Shwaish ,
Eugene Y. Hwang ,
Ravi Mandapati  and
Jesse W. Lee
Andrew S. Kato*
Affiliation:
Department of Pediatrics, Loma Linda Children’s Hospital, Loma Linda, CA, USA
Natalie S. Shwaish
Affiliation:
Department of Pediatrics, Division of Cardiology, Loma Linda Children’s Hospital, Loma Linda, CA, USA
Eugene Y. Hwang
Affiliation:
Pediatric Cardiology, Kaiser Permanente Fontana Medical Center. Fontana, CA, USA
Ravi Mandapati
Affiliation:
Department of Pediatrics, Division of Cardiology, Loma Linda Children’s Hospital, Loma Linda, CA, USA
Jesse W. Lee
Affiliation:
Department of Pediatrics, Division of Cardiology, Loma Linda Children’s Hospital, Loma Linda, CA, USA
*
Corresponding author: Andrew S. Kato; Email: akato@llu.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

We describe a case of novel use of trametinib in treating arrythmia without concomitant cardiomyopathy. Our patient is a two-year-old female born with Costello syndrome due to heterozygous mutations in the HRAS gene c34 G > T p (G12C). Shortly after birth, she was diagnosed with multifocal atrial tachyarrhythmia. Her imaging studies have shown no hypertrophy or CHD. There was poor arrhythmia control despite triple antiarrhythmic therapy. Trametinib, a MEK1 and MEK2 inhibitor, was used in treating her isolated atrial arrythmia, allowing her to wean off other antiarrhythmics. Other case reports have shown trametinib to benefit certain RASopathy patients with lymphatic abnormalities, hypertrophic cardiomyopathy, and concurrent arrhythmias. This case demonstrates effective treatment of isolated arrhythmia without cardiomyopathy, broadening the potential indications for use of trametinib in certain RASopathy patients.

Keywords

RASopathyCostello syndromeNoonan syndromeHRAS mutationTrametinibAtrial arrythmia

Information

Type
Brief Report
Information
Cardiology in the Young , Volume 34 , Issue 12 , December 2024 , pp. 2703 - 2705
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Gripp, KW, Morse, LA, Axelrad, M, et al. Costello syndrome: clinical phenotype, genotype, and management guidelines. Am J Med Genet 2019; 179(9): 1725–1744. DOI: 10.1002/ajmg.a.61270CrossRefGoogle ScholarPubMed
Jindal, GA, Goyal, Y, Burdine, RD, Rauen, KA, Shvartsman, SY. RASopathies: unraveling mechanisms with animal models [published correction appears in dis model mech. Dis Model Mech 2015; 8(9): 1167. Dis Model Mech; 8(8):769-782. DOI: 10.1242/dmm.020339CrossRefGoogle ScholarPubMed
Andelfinger, G, Marquis, C, Raboisson, MJ, et al. Hypertrophic cardiomyopathy in noonan syndrome treated by MEK-inhibition. J Am Coll Cardiolf 2019; 73(17): 2237–2239. DOI: 10.1016/j.jacc.2019.01.066 CrossRefGoogle ScholarPubMed
Geddes, G, Ware, S, Hussain, S, Parent, J. EP130: infantile hypertrophic cardiomyopathy due to HRAS related costello syndrome responsive to trametinib: outcomes after 2 years. Genetics in Medicine 2022; 24(3): S81. DOI: 10.1016/j.gim.2022.01.166 CrossRefGoogle Scholar
Levin, MD, Saitta, SC, Gripp, KW, et al. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients. Am J Med Genet A 2018; 176(8): 1711–1722. DOI: 10.1002/ajmg.a.38854 CrossRefGoogle ScholarPubMed
Meisner, JK, Bradley, DJ, Russell, MW. Molecular management of multifocal atrial tachycardia in noonan’s syndrome with MEK1/2 inhibitor trametinib. Circ Genom Precis Med 2021; 14(5): e003327. DOI: 10.1161/CIRCGEN.121.003327 CrossRefGoogle ScholarPubMed
Hebron, KE, Hernandez, ER, Yohe, ME. The RASopathies: from pathogenetics to therapeutics. Dis Model 2022; 15(2): dmm049107. DOI: 10.1242/dmm.04910 Google ScholarPubMed